The biosimulation market was sent into a tailspin in the closing months of 2025 as Certara (Nasdaq:CERT), a global leader in model-informed drug development, saw its market valuation crater by 23%. The precipitous drop followed a Q3 earnings report that, while beating on some bottom-line metrics, signaled a worrying
ArrowMark’s sharp reduction in its Alight stake comes at a moment when the market is questioning whether the company can turn its consulting-heavy work into steadier recurring revenue, and that tension may say more about sentiment than about the strength of the platform itself.
Top mid-cap stock performers last week: AGL, RXRX, CERT, AVAV, STRL, ORLA, IAG, SBSW, LOAR, RYTM, TLX. High gains due to positive news and macro uncertainty.
FDA introduces a new roadmap to reduce animal testing in monoclonal antibody development using AI models, organoid testing and real-world data to enhance safety and efficiency.
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
